Cerus Corp
NASDAQ:CERS

Watchlist Manager
Cerus Corp Logo
Cerus Corp
NASDAQ:CERS
Watchlist
Price: 1.82 USD 3.41% Market Closed
Market Cap: 338m USD
Have any thoughts about
Cerus Corp?
Write Note

Cerus Corp
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cerus Corp
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Cerus Corp
NASDAQ:CERS
Tax Provision
-$166k
CAGR 3-Years
21%
CAGR 5-Years
7%
CAGR 10-Years
-2%
Haemonetics Corp
NYSE:HAE
Tax Provision
-$35m
CAGR 3-Years
N/A
CAGR 5-Years
-40%
CAGR 10-Years
N/A
ICU Medical Inc
NASDAQ:ICUI
Tax Provision
-$97k
CAGR 3-Years
83%
CAGR 5-Years
58%
CAGR 10-Years
36%
Align Technology Inc
NASDAQ:ALGN
Tax Provision
-$199.5m
CAGR 3-Years
9%
CAGR 5-Years
-15%
CAGR 10-Years
-16%
Lantheus Holdings Inc
NASDAQ:LNTH
Tax Provision
-$142.6m
CAGR 3-Years
N/A
CAGR 5-Years
-100%
CAGR 10-Years
-85%
Merit Medical Systems Inc
NASDAQ:MMSI
Tax Provision
-$28.3m
CAGR 3-Years
-97%
CAGR 5-Years
-148%
CAGR 10-Years
-16%
No Stocks Found

Cerus Corp
Glance View

Market Cap
337.8m USD
Industry
Health Care

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

CERS Intrinsic Value
1.56 USD
Overvaluation 14%
Intrinsic Value
Price

See Also

What is Cerus Corp's Tax Provision?
Tax Provision
-166k USD

Based on the financial report for Sep 30, 2024, Cerus Corp's Tax Provision amounts to -166k USD.

What is Cerus Corp's Tax Provision growth rate?
Tax Provision CAGR 10Y
-2%

Over the last year, the Tax Provision growth was 69%. The average annual Tax Provision growth rates for Cerus Corp have been 21% over the past three years , 7% over the past five years , and -2% over the past ten years .

Back to Top